FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:860-863 February 23, 2006 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by McClung, M. R. PubMed Citation

In 2004, the Surgeon General's report on bone health highlighted osteoporosis as an important and growing national medical problem.¹ The authors of this report recognized that identification and treatment of this condition in women and men alike has lagged behind the increasing availability of instruments with which to detect low bone mass and the advancing pharmacologic approaches for prevention and therapy.

Lack of compliance with approved drug regimens can hinder progress in the treatment of osteoporosis.² In this issue of the Journal, from a study that was sponsored, designed, and analyzed by Amgen, McClung et al.³ report on the safety . . . [Full Text of this Article]

Source Information

From the Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis.

This article has been cited by other articles:

• Lewiecki, E. M. (2009). Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Therapeutic Advances in Musculoskeletal Diseases 1: 13-26 [Abstract]  
• Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., Christiansen, C., the FREEDOM Trial, (2009). Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. NEJM 361: 756-765 [Abstract] [Full Text]  
• Hegge, K. A., Fornoff, A. S., Gutierres, S. L., Haack, S. L. (2009). New Therapies for Osteoporosis. Journal of Pharmacy Practice 22: 53-64 [Abstract]  
• MacLaughlin, E. J., Raehl, C. L. (2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm 65: 343-357 [Full Text]  
• Vega, D., Maalouf, N. M., Sakhaee, K. (2007). The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. J. Clin. Endocrinol. Metab. 92: 4514-4521 [Abstract] [Full Text]